Anbogen Therapeutics, a clinical-stage biotechnology company, has successfully raised USD 7.3 million during an A+ financing round, following a USD 12.5 million Series A round closed in February 2024. The capital raised will be channeled towards the advanced clinical trial of ABT-301, a therapeutic for microsatellite stable (MSS) metastatic colorectal cancer. This cancer type represents 95% of metastatic colorectal cancers unresponsive to immune checkpoint inhibitors. Anbogen aims to utilize a synergistic effect between ABT-301 and PD-1 inhibitors, confirmed effective by preclinical studies. With strong support from investors led by KGI Venture Capital, this funding will also facilitate resource optimization via strategic partnerships for PD-1 drug supply. Dr. Tsu-An Hsu, CEO of Anbogen, commends the investor community for their confidence in the company’s mission to develop breakthrough cancer treatments. The company, founded by Dr. Joe Shih, has a robust pipeline including ABT-101 for non-small cell lung cancer and continues to leverage its extensive expertise in new drug development from its dedicated team.

Biotechnology, Pharmaceuticals, Venture Capital,Taiwan

https://contentapi.cision.com/api/v1.0/releases/20240701EN50060